Epivascular Glia Regression and Macular Pigment Restoration After Faricimab in Diabetic Retinopathy

Sponsor
Federico II University
Study ID
NCT07526857
Status
Completed

Conditions

  • Diabetic Retinopathy, DR

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Accepted

Interventions

  • Faricimab Injection [Vabysmo] — DRUG
    One group treated with faricimab and the other one treated with Aflibercept
  • Aflibercept (2.0 mg) — DRUG
    Aflibercept 2 mg intravitreal injection

Study Details

The aim of the study is to evaluate in diabetic patients affected by diabetic retinopathy epivascular glia regression and macular pigment restoration after faricimab injection in diabetic retinopathy in a 1 year follow up

Key Dates

Start date
Jan 1, 2025
Status verified
Apr 2026
Primary completion
Jan 1, 2026
Completion
Jan 1, 2026

Study Design

Enrollment
60 participants (actual)

Arms

  • Arm: Diabetic macular edema treated with Eylea 2 mg
    Diabetic macular edema treated with Eylea 2 mg
  • Arm: Diabetic macular edema treated with Faricimab

Primary Outcome Measure

Epivascular glia regression [ Time Frame: From January 2025 to January 2026 ]

Related Studies